Antipsychotic efficacy in psychosis with co-morbid cannabis misuse: A systematic review

Journal of Psychopharmacology

Volumn 30, Issue 2, 2016, Pages 99-111

  Wilson, Robin P ^a   Bhattacharyya, Sagnik ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Antipsychotic agents; cannabis; clozapine; psychotic disorders

Indexed keywords

CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

CANNABIS ADDICTION; COMORBIDITY; COMPARATIVE EFFECTIVENESS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MISUSE; DRUG USE; HUMAN; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; REVIEW; SYMPTOM; SYSTEMATIC REVIEW; COMPLICATION; MARIJUANA ABUSE; PATHOPHYSIOLOGY; PSYCHIATRIC DIAGNOSIS; PSYCHOTIC DISORDERS;

ANTIPSYCHOTIC AGENTS; DIAGNOSIS, DUAL (PSYCHIATRY); HUMANS; MARIJUANA ABUSE; PSYCHOTIC DISORDERS;

EID: 84955469036     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881115612237     Document Type: Review

References (85)

1. Akerele E, Levin FR, (2007) Comparison of olanzapine to risperidone in substance-abusing individuals with schizophrenia. Am J Addict 16: 260-268.
2. Baker AL, Hides L, Lubman DI, (2010) Treatment of cannabis use among people with psychotic or depressive disorders: a systematic review. J Clin Psychiatry 71: 247-254.
3. Baker AL, Thornton LK, Hides L, et al. (2012) Treatment of cannabis use among people with psychotic disorders: a critical review of randomised controlled trials. Curr Pharm Des 18: 4923-4937.
4. Balshem H, Helfand M, Schünemann HJ, et al. (2011) GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology 64: 401-406.
5. Barnett JH, Werners U, Secher SM, et al. (2007) Substance use in a population-based clinic sample of people with first-episode psychosis. Br J Psychiatry 190: 515-520.
6. Barrowclough C, Haddock G, Wykes T, et al. (2010) Integrated motivational interviewing and cognitive behavioural therapy for people with psychosis and comorbid substance misuse: randomised controlled trial. BMJ 341: c6325.
7. Berk M, Brook S, Trandafir AI, (1999) A comparison of olanzapine with haloperidol in cannabis-induced psychotic disorder: a double-blind randomized controlled trial. Int Clin Psychopharmacol 14: 177-180.
8. Berk S, Brook F, Nur M, (2000) Risperidone compared to haloperidol in cannabis-induced psychotic disorder: a double blind randomized controlled trial. Int J Psychiatry Clin Pract 4: 139-142.
9. Bhattacharyya S, Atakan Z, Martin-Santos R, et al. (2012a) Preliminary report of biological basis of sensitivity to the effects of cannabis on psychosis: AKT1 and DAT1 genotype modulates the effects of delta-9-tetrahydrocannabinol on midbrain and striatal function. Mol Psychiatry 17: 1152-1155.
10. Bhattacharyya S, Atakan Z, Martin-Santos R, et al. (2015a) Impairment of inhibitory control processing related to acute psychotomimetic effects of cannabis. Eur Neuropsychopharmacol 25: 26-37.
11. Bhattacharyya S, Crippa JA, Allen P, et al. (2012b) Induction of psychosis by δ9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing. Arch Gen Psychiatry 69: 27-36.
12. Bhattacharyya S, Falkenberg I, Martin-Santos R, et al. (2015b) Cannabinoid modulation of functional connectivity within regions processing attentional salience. Neuropsychopharmacology 40: 1343-52.
13. Bhattacharyya S, Fusar-Poli P, Borgwardt S, et al. (2009) Modulation of mediotemporal and ventrostriatal function in humans by Delta9-tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis. Arch Gen Psychiatry 66: 442-451.
14. Bhattacharyya S, Iyegbe C, Atakan Z, et al. (2014) Protein kinase B (AKT1) genotype mediates sensitivity to cannabis-induced impairments in psychomotor control. Psychol Med 44: 3315-3328.
15. Bossong MG, van Berckel BN, Boellaard R, et al. (2009) Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology 34: 759-766.
16. Brookes ST, Whitley E, Peters TJ, et al. (2001) Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives. Health Technol Assess 5: 1-56.
17. Brunette MF, Dawson R, O'Keefe CD, et al. (2011) A randomized trial of clozapine versus other antipsychotics for cannabis use disorder in patients with schizophrenia. J Dual Diagn 7: 50-63.
18. Brunette MF, Drake RE, Xie H, et al. (2006) Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders. Schizophr Bull 32: 637-643.
19. Cascini F, Aiello C, Di Tanna G, (2012) Increasing delta-9-tetrahydrocannabinol (δ-9-THC) content in herbal cannabis over time: systematic review and meta-analysis. Curr Drug Abuse Rev 5: 32-40.
20. Caspari D, (1999) Cannabis and schizophrenia: results of a follow-up study. Eur Arch Psychiatry Clin Neurosci 249: 45-49.
21. Conley RR, Kelly DL, Gale EA, (1998) Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse. Schizophr Res 33: 95-101.
22. Degenhardt L, Hall W, (2001) The association between psychosis and problematical drug use among Australian adults: findings from the National Survey of Mental Health and Well-Being. Psychol Med 31: 659-668.
23. Degenhardt L, Tennant C, Gilmour S, et al. (2007) The temporal dynamics of relationships between cannabis, psychosis and depression among young adults with psychotic disorders: findings from a 10-month prospective study. Psychol Med 37: 927-934.
24. Desseilles M, Mathot F, Desseilles M, (2008) Aripiprazole diminishes cannabis use in schizophrenia. J Neuropsychiatry Clin Neurosci 20: 117-118.
25. Drake RE, Xie H, McHugo GJ, et al. (2000) The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull 26: 441-449.
26. Ellenberg SS, Temple R, (2000) Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: practical issues and specific cases. Ann Intern Med 133: 464-470.
27. Foti DJ, Kotov R, Guey LT, et al. (2010) Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization. Am J Psychiatry 167: 987-993.
28. Grech A, Van Os J, Jones PB, et al. (2005) Cannabis use and outcome of recent onset psychosis. Eur Psychiatry 20: 349-353.
29. Green AI, Burgess ES, Dawson R, et al. (2003) Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone. Schizophr Res 60: 81-85.
30. Green AI, Tohen MF, Hamer RM, et al. (2004) First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr Res 66: 125-135.
31. Guyatt GH, Oxman AD, Vist G, et al. (2011) GRADE guidelines: 4. Rating the quality of evidence-study limitations (risk of bias). J Clin Epidemiol 64: 407-415.
32. Guyatt GH, Oxman AD, Vist GE, et al. (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336: 924-926.
33. Harris AW, Large MM, Redoblado-Hodge A, et al. (2010) Clinical and cognitive associations with aggression in the first episode of psychosis. Aust N Z J Psychiatry 44: 85-93.
34. Harrison I, Joyce EM, Mutsatsa SH, et al. (2008) Naturalistic follow-up of co-morbid substance use in schizophrenia: the West London first-episode study. Psychol Med 38: 79-88.
35. Henquet C, van Os J, Kuepper R, et al. (2010) Psychosis reactivity to cannabis use in daily life: an experience sampling study. Br J Psychiatry 196: 447-453.
36. Hides L, Dawe S, Kavanagh DJ, et al. (2006) Psychotic symptom and cannabis relapse in recent-onset psychosis. Prospective study. Br J Psychiatry 189: 137-143.
37. Hinton M, Edwards J, Elkins K, et al. (2007) Reductions in cannabis and other illicit substance use between treatment entry and early recovery in patients with first-episode psychosis. Early Interv Psychiatry 1: 259-266.
38. Hjorthøj C, Fohlmann A, Nordentoft M, (2009) Treatment of cannabis use disorders in people with schizophrenia spectrum disorders-a systematic review. Addict Behav 34: 520-525.
39. Hunt GE, Siegfried N, Morley K, et al. (2014) Psychosocial interventions for people with both severe mental illness and substance misuse. Schizophr Bull 40: 18-20.
40. Isaac M, Holloway F, (2005) Is cannabis an anti-antipsychotic? The experience in psychiatric intensive care. Hum Psychopharmacol 20: 207-210.
41. Khantzian EJ, (1985) The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. Am J Psychiatry 142: 1259-1264.
42. Koskinen J, Löhönen J, Koponen H, et al. (2010) Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis. Schizophr Bull 36: 1115-1130.
43. Kovasznay B, Fleischer J, Tanenberg-Karant M, et al. (1997) Substance use disorder and the early course of illness in schizophrenia and affective psychosis. Schizophr Bull 23: 195-201.
44. Kuepper R, van Os J, Lieb R, et al. (2011) Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. BMJ 342: d738.
45. Lazary J, (2012) Psychopharmacological boundaries of schizophrenia with comorbid cannabis use disorder: a critical review. Curr Pharm Des 18: 4890-4896.
46. Leweke FM, Piomelli D, Pahlisch F, et al. (2012) Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2: e94.
47. Lieberman JA, Tollefson G, Tohen M, et al. (2003) Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 160: 1396-1404.
48. Lingford-Hughes AR, Welch S, Peters L, et al. (2012) BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP. J Psychopharmacol 26: 899-952.
49. Linszen DH, Dingemans PM, Nugter MA, et al. (1997) Patient attributes and expressed emotion as risk factors for psychotic relapse. Schizophr Bull 23: 119-130.
50. Littrell KH, Petty RG, Hilligoss NM, et al. (2001) Olanzapine treatment for patients with schizophrenia and substance abuse. J Subst Abuse Treat 21: 217-221.
51. Machielsen M, Beduin AS, Dekker N, et al. (2012) Differences in craving for cannabis between schizophrenia patients using risperidone, olanzapine or clozapine. J Psychopharmacol 26: 189-195.
52. Machielsen MW, Veltman DJ, van den Brink W, et al. (2014) The effect of clozapine and risperidone on attentional bias in patients with schizophrenia and a cannabis use disorder: an fMRI study. J Psychopharmacol 28: 633-642.
53. Martín-Santos R, Fagundo AB, Crippa JA, et al. (2010) Neuroimaging in cannabis use: a systematic review of the literature. Psychol Med 40: 383-398.
54. Morgan CJ, Freeman TP, Schafer GL, et al. (2010) Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis. Neuropsychopharmacology 35: 1879-1885.
55. Negrete JC, Knapp WP, Douglas DE, et al. (1986) Cannabis affects the severity of schizophrenic symptoms: results of a clinical survey. Psychol Med 16: 515-520.
56. Nordström AL, Farde L, Nyberg S, et al. (1995) D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 152: 1444-1449.
57. Oxman AD, Sackett DL, Guyatt GH, et al. (1993) Users' guides to the medical literature: I. How to get started. JAMA 270: 2093-2095.
58. Patel R, Wilson R, Jackson R, et al. (2014) Association of cannabis use with hospital admission and treatment resistance in people with first episode psychosis in South London. Oral presentation at the 9th International Conference on Early Psychosis, Tokyo, Japan, 17-19 November 2014.
59. Porta N, Bonet C, Cobo E, (2007) Discordance between reported intention-to-treat and per protocol analyses. J Clin Epidemiol 60: 663-669.
60. Potvin S, Stip E, Lipp O, et al. (2006) Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorders: an open-label trial. Curr Med Res Opin 22: 1277-1285.
61. Potvin S, Stip E, Roy JY, (2004) The effect of quetiapine on cannabis use in 8 psychosis patients with drug dependency. Can J Psychiatry 49: 711.
62. Richardson WS, Wilson MC, Nishikawa J, et al. (1995) The well-built clinical question: a key to evidence-based decisions. ACP J Club 123: A12-13.
63. Rothwell PM, (2005) Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet 365: 176-186.
64. Rubio G, Martínez I, Ponce G, et al. (2006) Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Can J Psychiatry 51: 531-539.
65. Sami M, Rabiner EA, Bhattacharyya S, (2015) Does cannabis affect dopaminergic signaling in the Human brain? A systematic review of evidence to date. Eur Neuropsychopharmacol 25: 1201-1224.
66. San L, Arranz B, Martinez-Raga J, (2007) Antipsychotic drug treatment of schizophrenic patients with substance abuse disorders. Eur Addict Res 13: 230-243.
67. Schnell T, Koethe D, Krasnianski A, et al. (2014) Ziprasidone versus clozapine in the treatment of dually diagnosed (DD) patients with schizophrenia and cannabis use disorders: a randomized study. Am J Addict 23: 308-312.
68. Schoeler T, Monk A, Sami M, et al. (2015) Differential effects of continued versus discontinued cannabis use on outcome in patients with psychosis: a meta-analysis. Lancet Psychiatry, in press.
69. Schoeler T, Petros N, Behlke I, et al. (2014) Cannabis use as a predictor for relapse in first episode psychosis: a three-year follow-up study. Oral Abstracts. Early Intervention in Psychiatry 8 (Supplement 1): 32-62.
70. Sevy S, Robinson DG, Sunday S, et al. (2011) Olanzapine vs. risperidone in patients with first-episode schizophrenia and a lifetime history of cannabis use disorders: 16-week clinical and substance use outcomes. Psychiatry Res 188: 310-314.
71. Stokes PR, Mehta MA, Curran HV, et al. (2009) Can recreational doses of THC produce significant dopamine release in the human striatum? Neuroimage 48: 186-190.
72. Stuyt EB, Sajbel TA, Allen MH, (2006) Differing effects of antipsychotic medications on substance abuse treatment patients with co-occurring psychotic and substance abuse disorders. Am J Addict 15: 166-173.
73. Temple R, Ellenberg SS, (2000) Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues. Ann Intern Med 133: 455-463.
74. Turkington A, Mulholland CC, Rushe TM, et al. (2009) Impact of persistent substance misuse on 1-year outcome in first-episode psychosis. Br J Psychiatry 195: 242-248.
75. UNODC (2013) World Drug Report 2013 (United Nations publication, Sales No. E.13.XI.6).
76. van Nimwegen LJ, de Haan L, van Beveren NJ, et al. (2008) Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with schizophrenia or related disorders: a double-blind randomized controlled trial. Can J Psychiatry 53: 400-405.
77. Verdoux H, Liraud F, Gonzales B, et al. (2001) Predictors and outcome characteristics associated with suicidal behaviour in early psychosis: a two-year follow-up of first-admitted subjects. Acta Psychiatr Scand 103: 347-354.
78. Wade D, Harrigan S, Edwards J, et al. (2006) Substance misuse in first-episode psychosis: 15-month prospective follow-up study. Br J Psychiatry 189: 229-234.
79. Welge JA, Keck PE, (2003) Moderators of placebo response to antipsychotic treatment in patients with schizophrenia: a meta-regression. Psychopharmacology (Berl) 166: 1-10.
80. Wilkins JN, (1997) Pharmacotherapy of schizophrenia patients with comorbid substance abuse. Schizophr Bull 23: 215-228.
81. Woods SW, Gueorguieva RV, Baker CB, et al. (2005) Control group bias in randomized atypical antipsychotic medication trials for schizophrenia. Arch Gen Psychiatry 62: 961-970.
82. Wu HE, Okusaga OO, (2015) Antipsychotic medication-induced dysphoria: its meaning, association with typical vs. atypical medications and impact on adherence. Psychiatr Q 86: 199-205.
83. Zammit S, Moore TH, Lingford-Hughes A, et al. (2008) Effects of cannabis use on outcomes of psychotic disorders: systematic review. Br J Psychiatry 193: 357-363.
84. Zhornitsky S, Rizkallah E, Pampoulova T, et al. (2010) Antipsychotic agents for the treatment of substance use disorders in patients with and without comorbid psychosis. J Clin Psychopharmacol 30: 417-424.
85. Zimmet SV, Strous RD, Burgess ES, et al. (2000) Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey. J Clin Psychopharmacol 20: 94-98.